Exercise-BDNF-Mitophagy Biomarker Study in PD

Experiment Overview

Hypothesis being tested: Exercise-BDNF-Mitochondrial Resilience Hypothesis

Primary Objective: Determine whether physical exercise-induced BDNF elevation correlates with improved mitochondrial quality control markers and reduced neuroinflammation in Parkinson's Disease patients.

Study Design: Prospective cohort study with 12-month follow-up

Study Population

Inclusion Criteria

• Age 45-75 years
• Diagnosis of idiopathic Parkinson's Disease (UK Brain Bank criteria)
• Hoehn & Yahr stage 1-3
• Stable dopaminergic medication for ≥4 weeks
• Able to participate in moderate exercise program

Exclusion Criteria

• Secondary parkinsonism
• Significant cardiovascular disease
• Orthopedic limitations preventing exercise
• Already engaged in structured exercise (>150 min/week)
• Cognitive impairment (MoCA <24)

Sample Size

• Total: 120 participants (60 exercise, 60 control)
• Power: 80% power to detect 20% difference in BDNF levels (α=0.05)
• Stratification: Equal BDNF Val66Met genotype distribution in both arms

Study Arms

Exercise Intervention Group (n=60)

• Type: Aerobic exercise (treadmill, cycling)
• Duration: 12 months
• Frequency: 3 sessions/week
• Intensity: 60-75% heart rate reserve
• Supervision: Bi-weekly in-person, home-based with weekly check-ins

Control Group (n=60)

• Intervention: Stretching and flexibility exercises (non-aerobic)
• Duration: 12 months
• Frequency: 2 sessions/week
• Intensity: Low intensity (RPE <10)

Outcome Measures

...

Experiment Overview

Hypothesis being tested: Exercise-BDNF-Mitochondrial Resilience Hypothesis

Primary Objective: Determine whether physical exercise-induced BDNF elevation correlates with improved mitochondrial quality control markers and reduced neuroinflammation in Parkinson's Disease patients.

Study Design: Prospective cohort study with 12-month follow-up

Study Population

Inclusion Criteria

• Age 45-75 years
• Diagnosis of idiopathic Parkinson's Disease (UK Brain Bank criteria)
• Hoehn & Yahr stage 1-3
• Stable dopaminergic medication for ≥4 weeks
• Able to participate in moderate exercise program

Exclusion Criteria

• Secondary parkinsonism
• Significant cardiovascular disease
• Orthopedic limitations preventing exercise
• Already engaged in structured exercise (>150 min/week)
• Cognitive impairment (MoCA <24)

Sample Size

• Total: 120 participants (60 exercise, 60 control)
• Power: 80% power to detect 20% difference in BDNF levels (α=0.05)
• Stratification: Equal BDNF Val66Met genotype distribution in both arms

Study Arms

Exercise Intervention Group (n=60)

• Type: Aerobic exercise (treadmill, cycling)
• Duration: 12 months
• Frequency: 3 sessions/week
• Intensity: 60-75% heart rate reserve
• Supervision: Bi-weekly in-person, home-based with weekly check-ins

Control Group (n=60)

• Intervention: Stretching and flexibility exercises (non-aerobic)
• Duration: 12 months
• Frequency: 2 sessions/week
• Intensity: Low intensity (RPE <10)

Outcome Measures

Primary Outcomes

| Measure | Timepoints | Method |
|---------|------------|--------|
| Serum BDNF | Baseline, 3, 6, 12 months | ELISA |
| Serum Parkin | Baseline, 3, 6, 12 months | ELISA |
| Serum PINK1 | Baseline, 3, 6, 12 months | ELISA |
| UPDRS Part III (Motor) | Baseline, 3, 6, 12 months | Clinical exam |

Secondary Outcomes

| Measure | Timepoints | Method |
|---------|------------|--------|
| Neuroinflammation (IL-6, TNF-α) | Baseline, 6, 12 months | Multiplex ELISA |
| Mitochondrial DNA copy number | Baseline, 6, 12 months | qPCR |
| CSF BDNF (subset n=30) | Baseline, 12 months | ELISA |
| Autonomic function (SCOPA-AUT) | Baseline, 12 months | Questionnaire |
| Quality of life (PDQ-39) | Baseline, 6, 12 months | Questionnaire |

Exploratory Outcomes

• Gut [microbiome](/entities/microbiome) composition (16S rRNA sequencing)
• Peripheral inflammatory monocytes (flow cytometry)
• Exosomal [alpha-synuclein](/proteins/alpha-synuclein)

BDNF Genotyping

Genotype Stratification

All participants genotyped for BDNF Val66Met polymorphism (rs6265):

• Val/Val: Expected normal BDNF trafficking
• Val/Met: Reduced activity-dependent BDNF secretion
• Met/Met: Significantly impaired BDNF release

Hypothesized Effect Modification

The exercise-BDNF relationship may be attenuated in Met carriers due to impaired BDNF trafficking. This will be tested via interaction analysis.

Statistical Analysis Plan

Primary Analysis

• Mixed-effects linear regression (group × time interaction)
• Adjusted for: age, sex, disease duration, baseline UPDRS, medication dose

Secondary Analyses

• Correlation: ΔBDNF vs ΔUPDRS, ΔBDNF vs mitochondrial markers
• Genotype stratification: Compare effect sizes by Val66Met genotype
• Mediation analysis: Does change in inflammatory markers mediate BDNF-motor association?

Power Calculation

• n=60/group provides 80% power to detect:
• 25% increase in serum BDNF (Cohen's d=0.5)
• 15% reduction in UPDRS progression

Data Collection Schedule

Risk Assessment

Potential Risks

• Exercise-related musculoskeletal injury
• Fatigue during exercise sessions
• Blood draw discomfort

Mitigation Strategies

• Supervised exercise program with gradual progression
• Exclusion of participants with cardiovascular contraindication
• Standard phlebotomy protocols

Expected Benefits

• Improved motor function
• Enhanced quality of life
• Potential disease-modifying effects (mechanistic)

Budget Estimate

| Item | Cost |
|------|------|
| Personnel (2 research coordinators) | 20,000 |
| BDNF/Parkin/PINK1 ELISAs (720 assays) | 3,200 |
| Inflammatory marker panel (240 assays) | 4,400 |
| Genotyping (120 samples) | ,600 |
| Exercise equipment/supervision | 5,000 |
| Participant compensation | 6,000 |
| CSF collection (30 samples) | ,000 |
| Total | 51,200 |

Ethical Considerations

• IRB approval required
• Informed consent for genotyping
• Genetic counseling available for participants
• Data safety monitoring board for adverse events

Expected Timeline

• Month 0-2: IRB approval, recruitment start
• Month 2-14: Enrollment (12 months)
• Month 14-26: Follow-up completion
• Month 26-30: Data analysis and manuscript preparation

See Also

• [Experiment Index](/experiments/experiment-index)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References

[Unknown, Physical activity and Parkinson disease risk (JAMA Neurol 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30668840/)

[Unknown, BDNF Val66Met polymorphism and exercise (Nat Rev Neurosci 2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17684528/)

[Unknown, Exercise increases serum BDNF in humans (J Appl Physiol 2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29327843/)

[Unknown, Mitophagy in Parkinson's disease (Nat Rev Neurol 2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30610316/)

[Unknown, BDNF and dopaminergic neuron survival (Exp Neurol 2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12445574/)